Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a staggering $4.3 billion, a move that substantially strengthens Gilead’s position in the liver disease treatment landscape. The acquisition brings CymaBay’s leading investigational product, seladelpar, under Gilead’s expanding liver portfolio, marking a significant step forward in the […]
In a significant move within the biopharmaceutical industry, Gilead Sciences, Inc. (Nasdaq: GILD) has confirmed its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for a notable $32.50 per share in cash, culminating in a total equity value of $4.3 billion. This strategic acquisition brings CymaBay’s leading investigational product, seladelpar, into Gilead’s portfolio, potentially transforming the […]
Indian pharmaceutical company Lupin has announced its approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Obeticholic Acid Tablets, 5 mg and 10 mg. In March 2023, Lupin was issued tentative approval for Obeticholic Acid Tablets, 5 mg and 10 mg from the FDA. These tablets are […]
Lupin said that it has been issued tentative approval for Obeticholic Acid Tablets, 5 mg and 10 mg from the US Food and Drug Administration (FDA). The Indian pharma company approval is for the abbreviated new drug application (ANDA) for marketing a generic version of Intercept Pharmaceuticals’ Ocaliva Tablets, 5 mg and 10 mg. As […]
Cadila Healthcare (Zydus Cadilla) said that it has obtained permission from the US Food and Drug Administration (FDA) to launch the phase 2(b)/3 clinical trial of saroglitazar magnesium in primary biliary cholangitis (PBC). The late-stage trial, designed to assess the efficacy and safety of saroglitazar magnesium, will have 192 patients. The participants will be randomly […]
GENFIT has started the phase 3 ELATIVE clinical trial for evaluating the efficacy and safety of elafibranor for the treatment of primary biliary cholangitis (PBC). According to the French pharma company, ELATIVE is a randomized, double blind, placebo-controlled, global multicenter phase 3 study. Elafibranor is a dual PPAR alpha and delta agonist in primary biliary […]
